--- title: "RAD-140 (Testolone): Dosing & Vendor Prices" description: "RAD-140 (Testolone): dosing protocols, mechanism & side effects. Compare 1 verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "RAD-140 (Testolone)" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "RAD-140 (Testolone)", "description": "RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290). Radius took it into oncology rather than into muscle wasting, and the only registered human trial is a phase 1 study in postmenopausal women with hormone receptor positive metastatic breast cancer. It is not approved by any regulator. The molecule binds the androgen receptor and acts as an agonist, changing which androgen-responsive genes are transcribed. The human phase 1 study used sex hormone binding globulin and prostate-specific antigen as markers of that engagement and saw sex hormone binding globulin fall in all 18 evaluable patients and prostate-specific antigen rise in 16 of 20, with paired tumor biopsies confirming receptor engagement (PMID: 34565686). Preclinical work covers three separate claims. For neuroprotection, RAD-140 reduced apoptotic cell death in cultured rat hippocampal neurons and protected hippocampal neurons in kainate-lesioned male rats, with the effect depending on MAPK signaling (PMID: 24428527). For oncology, it inhibited growth of androgen receptor positive and estrogen receptor positive breast cancer models (PMID: 28974548). For muscle, a study in young male Sprague-Dawley rats found increased muscle fiber cross-sectional area in unloaded animals but no additional benefit when combined with functional overload, and no change in cortical or trabecular bone over 14 days (PMID: 40680216). Two mouse studies point the other way on health span: in female mice, ten weeks of RAD140 increased frailty and mortality risk and failed to improve strength (PMID: 37758180), and a later study in older male and female mice again reported an effect on frailty (PMID: 40158703). The human safety signal is the clearest reason this compound is not a casual purchase. In the phase 1 cancer study, the most frequent treatment-emergent adverse events were raised aspartate aminotransferase in 59.1 percent, raised alanine aminotransferase in 45.5 percent and raised total bilirubin in 27.3 percent, and grade 3 or 4 events occurred in 72.7 percent of the 22 patients (PMID: 34565686). Outside trials, biopsy-confirmed cholestatic drug-induced liver injury after RAD-140 has been reported repeatedly, with peak total bilirubin far above normal and recovery taking months (PMID: 36561105, PMID: 36945289, PMID: 39328701, PMID: 36978171, PMID: 38444893). There are also cardiac case reports: acute myocarditis (PMID: 35233331), myopericarditis in a 16-year-old boy after a first dose (PMID: 39157568) and heart failure (PMID: 38864168). RAD140 is named in FDA warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025), and it is prohibited in sport at all times under the World Anti-Doping Agency anabolic agents class (PMID: 28137616).", "url": "https://www.bodyhackguide.co/compound/rad-140", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "84.99", "highPrice": "84.99", "priceCurrency": "USD", "offerCount": "1", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "84.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/rad-140/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" } } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "RAD-140 (Testolone)", "description": "RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290). Radius took it into oncology rather than into muscle wasting, and the only registered human trial is a phase 1 study in postmenopausal women with hormone receptor positive metastatic breast cancer. It is not approved by any regulator. The molecule binds the androgen receptor and acts as an agonist, changing which androgen-responsive genes are transcribed. The human phase 1 study used sex hormone binding globulin and prostate-specific antigen as markers of that engagement and saw sex hormone binding globulin fall in all 18 evaluable patients and prostate-specific antigen rise in 16 of 20, with paired tumor biopsies confirming receptor engagement (PMID: 34565686). Preclinical work covers three separate claims. For neuroprotection, RAD-140 reduced apoptotic cell death in cultured rat hippocampal neurons and protected hippocampal neurons in kainate-lesioned male rats, with the effect depending on MAPK signaling (PMID: 24428527). For oncology, it inhibited growth of androgen receptor positive and estrogen receptor positive breast cancer models (PMID: 28974548). For muscle, a study in young male Sprague-Dawley rats found increased muscle fiber cross-sectional area in unloaded animals but no additional benefit when combined with functional overload, and no change in cortical or trabecular bone over 14 days (PMID: 40680216). Two mouse studies point the other way on health span: in female mice, ten weeks of RAD140 increased frailty and mortality risk and failed to improve strength (PMID: 37758180), and a later study in older male and female mice again reported an effect on frailty (PMID: 40158703). The human safety signal is the clearest reason this compound is not a casual purchase. In the phase 1 cancer study, the most frequent treatment-emergent adverse events were raised aspartate aminotransferase in 59.1 percent, raised alanine aminotransferase in 45.5 percent and raised total bilirubin in 27.3 percent, and grade 3 or 4 events occurred in 72.7 percent of the 22 patients (PMID: 34565686). Outside trials, biopsy-confirmed cholestatic drug-induced liver injury after RAD-140 has been reported repeatedly, with peak total bilirubin far above normal and recovery taking months (PMID: 36561105, PMID: 36945289, PMID: 39328701, PMID: 36978171, PMID: 38444893). There are also cardiac case reports: acute myocarditis (PMID: 35233331), myopericarditis in a 16-year-old boy after a first dose (PMID: 39157568) and heart failure (PMID: 38864168). RAD140 is named in FDA warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025), and it is prohibited in sport at all times under the World Anti-Doping Agency anabolic agents class (PMID: 28137616).", "lastReviewed": "2026-09-07T04:47:47.716Z", "url": "https://www.bodyhackguide.co/compound/rad-140", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "RAD-140 (Testolone)", "alternateName": [ "Testolone", "RAD140", "RAD 140", "Vosilasarm", "Testalone" ], "description": "RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290). Radius took it into oncology rather than into muscle wasting, and the only registered human trial is a phase 1 study in postmenopausal women with hormone receptor positive metastatic breast cancer. It is not approved by any regulator. The molecule binds the androgen receptor and acts as an agonist, changing which androgen-responsive genes are transcribed. The human phase 1 study used sex hormone binding globulin and prostate-specific antigen as markers of that engagement and saw sex hormone binding globulin fall in all 18 evaluable patients and prostate-specific antigen rise in 16 of 20, with paired tumor biopsies confirming receptor engagement (PMID: 34565686). Preclinical work covers three separate claims. For neuroprotection, RAD-140 reduced apoptotic cell death in cultured rat hippocampal neurons and protected hippocampal neurons in kainate-lesioned male rats, with the effect depending on MAPK signaling (PMID: 24428527). For oncology, it inhibited growth of androgen receptor positive and estrogen receptor positive breast cancer models (PMID: 28974548). For muscle, a study in young male Sprague-Dawley rats found increased muscle fiber cross-sectional area in unloaded animals but no additional benefit when combined with functional overload, and no change in cortical or trabecular bone over 14 days (PMID: 40680216). Two mouse studies point the other way on health span: in female mice, ten weeks of RAD140 increased frailty and mortality risk and failed to improve strength (PMID: 37758180), and a later study in older male and female mice again reported an effect on frailty (PMID: 40158703). The human safety signal is the clearest reason this compound is not a casual purchase. In the phase 1 cancer study, the most frequent treatment-emergent adverse events were raised aspartate aminotransferase in 59.1 percent, raised alanine aminotransferase in 45.5 percent and raised total bilirubin in 27.3 percent, and grade 3 or 4 events occurred in 72.7 percent of the 22 patients (PMID: 34565686). Outside trials, biopsy-confirmed cholestatic drug-induced liver injury after RAD-140 has been reported repeatedly, with peak total bilirubin far above normal and recovery taking months (PMID: 36561105, PMID: 36945289, PMID: 39328701, PMID: 36978171, PMID: 38444893). There are also cardiac case reports: acute myocarditis (PMID: 35233331), myopericarditis in a 16-year-old boy after a first dose (PMID: 39157568) and heart failure (PMID: 38864168). RAD140 is named in FDA warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025), and it is prohibited in sport at all times under the World Anti-Doping Agency anabolic agents class (PMID: 28137616).", "activeIngredient": "RAD-140 (Testolone)", "administrationRoute": "Oral", "mechanismOfAction": "RAD-140 is a nonsteroidal agonist of the androgen receptor built on a 1,3,4-oxadiazole scaffold (PMID: 24900290). It binds the receptor and drives transcription of androgen-responsive genes, producing anabolic effects in muscle in rats (PMID: 40680216) and neuroprotective effects in rat hippocampal neurons that depend on MAPK signaling (PMID: 24428527). Human target engagement was documented directly in a phase 1 study: sex hormone binding globulin fell in every evaluable patient and prostate-specific antigen rose in most, with paired tumor biopsies showing androgen receptor engagement (PMID: 34565686). In estrogen receptor positive breast cancer models, androgen receptor activation by RAD140 suppressed tumor growth through a mechanism distinct from estrogen receptor blockade (PMID: 28974548).", "dosageForm": "capsule", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is RAD-140 (Testolone) used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290). Radius took it into oncology rather than into muscle wasting, and the only registered human trial is a phase 1 study in postmenopausal women with hormone receptor positive metastatic breast cancer. It is not approved by any regulator. The molecule binds the androgen receptor and acts as an agonist, changing which androgen-responsive genes are transcribed. The human phase 1 study used sex hormone binding globulin and prostate-specific antigen as markers of that engagement and saw sex hormone binding globulin fall in all 18 evaluable patients and prostate-specific antigen rise in 16 of 20, with paired tumor biopsies confirming receptor engagement (PMID: 34565686). Preclinical work covers three separate claims. For neuroprotection, RAD-140 reduced apoptotic cell death in cultured rat hippocampal neurons and protected hippocampal neurons in kainate-lesioned male rats, with the effect depending on MAPK signaling (PMID: 24428527). For oncology, it inhibited growth of androgen receptor positive and estrogen receptor positive breast cancer models (PMID: 28974548). For muscle, a study in young male Sprague-Dawley rats found increased muscle fiber cross-sectional area in unloaded animals but no additional benefit when combined with functional overload, and no change in cortical or trabecular bone over 14 days (PMID: 40680216). Two mouse studies point the other way on health span: in female mice, ten weeks of RAD140 increased frailty and mortality risk and failed to improve strength (PMID: 37758180), and a later study in older male and female mice again reported an effect on frailty (PMID: 40158703). The human safety signal is the clearest reason this compound is not a casual purchase. In the phase 1 cancer study, the most frequent treatment-emergent adverse events were raised aspartate aminotransferase in 59.1 percent, raised alanine aminotransferase in 45.5 percent and raised total bilirubin in 27.3 percent, and grade 3 or 4 events occurred in 72.7 percent of the 22 patients (PMID: 34565686). Outside trials, biopsy-confirmed cholestatic drug-induced liver injury after RAD-140 has been reported repeatedly, with peak total bilirubin far above normal and recovery taking months (PMID: 36561105, PMID: 36945289, PMID: 39328701, PMID: 36978171, PMID: 38444893). There are also cardiac case reports: acute myocarditis (PMID: 35233331), myopericarditis in a 16-year-old boy after a first dose (PMID: 39157568) and heart failure (PMID: 38864168). RAD140 is named in FDA warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025), and it is prohibited in sport at all times under the World Anti-Doping Agency anabolic agents class (PMID: 28137616)." } }, { "@type": "Question", "name": "What forms does RAD-140 (Testolone) come in?", "acceptedAnswer": { "@type": "Answer", "text": "RAD-140 (Testolone) is available in capsule form." } }, { "@type": "Question", "name": "How much does RAD-140 (Testolone) cost?", "acceptedAnswer": { "@type": "Answer", "text": "Prices start at $84.99 across 1 verified vendor." } }, { "@type": "Question", "name": "How do I compare RAD-140 (Testolone) vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Frad-140) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. RAD-140 (Testolone) [Where to buy RAD-140 (Testolone)](/buy/rad-140) [RAD-140 (Testolone) coupon codes](/coupons/rad-140) [RAD-140 (Testolone) protocol](/protocol/rad-140) [Alternatives to RAD-140 (Testolone)](/alternatives-to/rad-140) [RAD-140 (Testolone) side effects](/side-effects/rad-140) 1. [Home](/) 3. [Compounds](/compare) 5. RAD-140 (Testolone) ![RAD-140 (Testolone) molecular structure](/assets/peptide-structure-placeholder-DUmZBF_j.png) # RAD-140 (Testolone) Performance Phase 1 Download PDF Also known as: Testolone, RAD140, RAD 140, Vosilasarm, Testalone RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290). Radius took it into oncology rather than into muscle wasting, and the only registered human trial is a phase 1 study in postmenopausal women with hormone receptor positive metastatic breast cancer. Half-Life: Terminal half-life 44.7 hours in humans, measured in a first-in-human phase 1 study in postmenopausal women with metastatic breast cancer (PMID: 34565686) Route: Oral MW: 393.83 g/mol CAS: 1182367-47-0 Last reviewed: Sep 7, 2026 [ Performance Category ](/wiki#cat-performance) Phase 1 Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare Prices1 Related ## Overview ### Best Price Available ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $84.99 60 capsules · capsule [Buy Now](https://disguisedalpha.com/product/rad-140/?coupon=reddit) Compare 1 vendor ### At A Glance Mechanism RAD-140 is a nonsteroidal agonist of the androgen receptor built on a 1,3,4-oxadiazole scaffold (PMID: 24900290). It binds the receptor and drives transcription of androgen-responsive genes, producing anabolic effects in muscle in rats (PMID: 40680216) and neuroprotective effects… Half-Life Terminal half-life 44.7 hours in humans, measured in a first-in-human phase 1 study in postmenopausal women with metastatic breast cancer (PMID: 34565686) Routes Oral Potential Benefits Reduced apoptotic neuron death in cultured rat hippocampal neurons and protected hippocampal neurons in kainate-lesioned male rats (PMID: 24428527) Inhibited growth of androgen receptor positive and estrogen receptor positive breast cancer models, including in animal studies (PMID: 28974548) Increased muscle fiber cross-sectional area in young male Sprague-Dawley rats, without additional benefit on top of functional overload and without change in bone microarchitecture over 14 days (PMID: 40680216) Documented androgen receptor engagement in humans, with sex hormone binding globulin falling in all 18 evaluable patients in a phase 1 study (PMID: 34565686) One partial response and an 18.2 percent clinical benefit rate at 24 weeks in heavily pretreated metastatic breast cancer in that phase 1 study (PMID: 34565686) ### Overview RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290). Radius took it into oncology rather than into muscle wasting, and the only registered human trial is a phase 1 study in postmenopausal women with hormone receptor positive metastatic breast cancer. It is not approved by any regulator. The molecule binds the androgen receptor and acts as an agonist, changing which androgen-responsive genes are transcribed. The human phase 1 study used sex hormone binding globulin and prostate-specific antigen as markers of that engagement and saw sex hormone binding globulin fall in all 18 evaluable patients and prostate-specific antigen rise in 16 of 20, with paired tumor biopsies confirming receptor engagement (PMID: 34565686). Preclinical work covers three separate claims. For neuroprotection, RAD-140 reduced apoptotic cell death in cultured rat hippocampal neurons and protected hippocampal neurons in kainate-lesioned male rats, with the effect depending on MAPK signaling (PMID: 24428527). For oncology, it inhibited growth of androgen receptor positive and estrogen receptor positive breast cancer models (PMID: 28974548). For muscle, a study in young male Sprague-Dawley rats found increased muscle fiber cross-sectional area in unloaded animals but no additional benefit when combined with functional overload, and no change in cortical or trabecular bone over 14 days (PMID: 40680216). Two mouse studies point the other way on health span: in female mice, ten weeks of RAD140 increased frailty and mortality risk and failed to improve strength (PMID: 37758180), and a later study in older male and female mice again reported an effect on frailty (PMID: 40158703). The human safety signal is the clearest reason this compound is not a casual purchase. In the phase 1 cancer study, the most frequent treatment-emergent adverse events were raised aspartate aminotransferase in 59.1 percent, raised alanine aminotransferase in 45.5 percent and raised total bilirubin in 27.3 percent, and grade 3 or 4 events occurred in 72.7 percent of the 22 patients (PMID: 34565686). Outside trials, biopsy-confirmed cholestatic drug-induced liver injury after RAD-140 has been reported repeatedly, with peak total bilirubin far above normal and recovery taking months (PMID: 36561105, PMID: 36945289, PMID: 39328701, PMID: 36978171, PMID: 38444893). There are also cardiac case reports: acute myocarditis (PMID: 35233331), myopericarditis in a 16-year-old boy after a first dose (PMID: 39157568) and heart failure (PMID: 38864168). RAD140 is named in FDA warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025), and it is prohibited in sport at all times under the World Anti-Doping Agency anabolic agents class (PMID: 28137616). ### Potential Research Fields Oncology Neuroprotection Muscle and bone anabolism Hepatotoxicity surveillance ## Chemical Information IUPAC Name Not yet available CAS Number 1182367-47-0 Molecular Formula C20H16ClN5O2 Molecular Mass 393.83 g/mol ![RAD-140 (Testolone) molecular structure](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/44200882/PNG) [View on PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/44200882) ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications Mechanism-based: contraindicated in pregnancy, since androgen receptor agonists can virilize a female fetus, and in men with known or suspected prostate cancer. Pre-existing liver disease or raised transaminases is both mechanism-based and case-report-based, given how frequently transaminase and bilirubin rises appeared in the phase 1 trial and in published liver injury reports (PMID: 34565686, PMID: 36945289). Cardiac case reports, including one in a 16-year-old, are a reason to avoid it in anyone with known cardiac disease (PMID: 39157568, PMID: 38864168). Prohibited in tested sport at all times (PMID: 28137616). Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $84.99 Best $/mg — Vendors 1 Listings 1 capsule [Sign in for alerts ](/auth) Form Allcapsule Sort Price $/mg Vendor Vendor Product Form Qty Price $/mg Coupon ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) [Disguised Alpha](/vendor/disguised-alpha) [50 ](/vendor-trust-scorecard) 🇺🇸 US 🇪🇺 EU 🇬🇧 UK RAD-140 capsules (60) capsule 60 capsules ● In Stock $84.99 BEST — — [Buy](https://disguisedalpha.com/product/rad-140/?coupon=reddit) Get RAD-140 (Testolone) Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. Current lowest: $84.99 [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with RAD-140 (Testolone). [Sign in](/auth) Current low $84.99 as of Sep 7, 2026 7-day low $84.99 30-day low $84.99 30-day change — baseline building Tracking since Sep 7, 2026 · 1 data point ### Vendors Selling RAD-140 (Testolone) [ ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) #### Disguised Alpha 1 listing · from $84.99 ](/vendor/disguised-alpha) How we score these vendors Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. [View Scorecard](/vendors/scorecard) ### Related Compounds [View All](/wiki) [ ### ITPP Performance Preclinical ITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues. Research compound — IV infusion in studies, no established oral doses 36 studies View Profile ](/compound/itpp)[ ### LGD-4033 (Ligandrol) Performance Phase 2 LGD-4033, usually sold as ligandrol, is a nonsteroidal selective androgen receptor modulator that Viking Therapeutics took into clinical development under the code VK5211 (NCT02578095). t½ Long elimination half-life in humans with dose-proportional accumulation over 21 days of daily dosing in healthy young men; the report describes the profile without giving a single value in its summary (PMID: 22459616) Preclinical View Profile ](/compound/lgd-4033)[ ### Ostarine (Enobosarm, MK-2866) Performance Phase 3 Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22. t½ Not established from a retrieved human report; in rats the mean elimination half-life of radiolabeled GTx-024 was 0.6 h in males and 16.4 h in females (PMID: 24074268). Human plasma pharmacokinetics were characterized in phase 1 drug-interaction studies (PMID: 27105861) Preclinical View Profile ](/compound/ostarine)[ ### PEG-MGF Performance Preclinical PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of Mechano Growth Factor (MGF) — an alternatively spliced variant of IGF-1 produced locally in muscle and other tissues in response to mechanical loading or damage. t½ Native MGF: very short (minutes) due to rapid proteolysis. PEG-MGF: PEGylation is intended to extend this substantially (community estimates up to roughly 1 day), but there are no published human pharmacokinetic data to confirm a specific value. 200 Preclinical View Profile ](/compound/peg-mgf)[ ### SLU-PP-332 Performance Preclinical SLU-PP-332 is the first-generation synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by the laboratory of Thomas Burris at Saint Louis University and reported in a landmark 2023 publication that established ERR pan-agonism as a pharmacologically tractable exercise-mimetic drug mechanism. Research compound — no established human doses. Animal studies: 10-50 mg/kg 8 studies View Profile ](/compound/slu-pp-332)[ ### YK-11 Performance Preclinical YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. t½ Not established. In a human elimination study using deuterium-labeled YK-11, no intact parent compound was seen in urine; unconjugated metabolites disappeared within 24 hours and glucuronidated and sulfated metabolites remained traceable beyond 48 hours (PMID: 30379415) Preclinical View Profile ](/compound/yk-11) [ View Full Dosage Guide → Protocols, calculator & safety for RAD-140 (Testolone) ](/guides/dosage/rad-140) ### Best Price ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $84.99 [Buy Now](https://disguisedalpha.com/product/rad-140/?coupon=reddit) 1 vendors · 1 listings ### Research Score 30 0 PubMed studies ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings ### Quick Facts Half-Life Terminal half-life 44.7 hours in humans, measured in a first-in-human phase 1 study in postmenopausal women with metastatic breast cancer (PMID: 34565686) Molecular Weight 393.83 g/mol Administration Oral CAS Number 1182367-47-0 Trial Phase Phase 1 0 [Full Dosage Guide](/guides/dosage/rad-140)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is RAD-140 (Testolone) used for in research? RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290). Radius took it into oncology rather than into muscle wasting, and the only registered human trial is a phase 1 study in postmenopausal women with hormone receptor positive metastatic breast cancer. It is not approved by any regulator. The molecule binds the androgen receptor and acts as an agonist, changing which androgen-responsive genes are transcribed. The human phase 1 study used sex hormone binding globulin and prostate-specific antigen as markers of that engagement and saw sex hormone binding globulin fall in all 18 evaluable patients and prostate-specific antigen rise in 16 of 20, with paired tumor biopsies confirming receptor engagement (PMID: 34565686). Preclinical work covers three separate claims. For neuroprotection, RAD-140 reduced apoptotic cell death in cultured rat hippocampal neurons and protected hippocampal neurons in kainate-lesioned male rats, with the effect depending on MAPK signaling (PMID: 24428527). For oncology, it inhibited growth of androgen receptor positive and estrogen receptor positive breast cancer models (PMID: 28974548). For muscle, a study in young male Sprague-Dawley rats found increased muscle fiber cross-sectional area in unloaded animals but no additional benefit when combined with functional overload, and no change in cortical or trabecular bone over 14 days (PMID: 40680216). Two mouse studies point the other way on health span: in female mice, ten weeks of RAD140 increased frailty and mortality risk and failed to improve strength (PMID: 37758180), and a later study in older male and female mice again reported an effect on frailty (PMID: 40158703). The human safety signal is the clearest reason this compound is not a casual purchase. In the phase 1 cancer study, the most frequent treatment-emergent adverse events were raised aspartate aminotransferase in 59.1 percent, raised alanine aminotransferase in 45.5 percent and raised total bilirubin in 27.3 percent, and grade 3 or 4 events occurred in 72.7 percent of the 22 patients (PMID: 34565686). Outside trials, biopsy-confirmed cholestatic drug-induced liver injury after RAD-140 has been reported repeatedly, with peak total bilirubin far above normal and recovery taking months (PMID: 36561105, PMID: 36945289, PMID: 39328701, PMID: 36978171, PMID: 38444893). There are also cardiac case reports: acute myocarditis (PMID: 35233331), myopericarditis in a 16-year-old boy after a first dose (PMID: 39157568) and heart failure (PMID: 38864168). RAD140 is named in FDA warning letters to firms selling SARM products as unapproved new drugs (FDA warning letter to Titan SARMs LLC, 12 December 2025), and it is prohibited in sport at all times under the World Anti-Doping Agency anabolic agents class (PMID: 28137616). What forms does RAD-140 (Testolone) come in? RAD-140 (Testolone) is available in capsule form. How much does RAD-140 (Testolone) cost? Prices start at $84.99 across 1 verified vendor. How do I compare RAD-140 (Testolone) vendors? Compare prices, payment methods, shipping, and COA scores across 1 vendor. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### ITPP Performance Preclinical ITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues. Research compound — IV infusion in studies, no established oral doses 36 studies View Profile ](/compound/itpp)[ ### LGD-4033 (Ligandrol) Performance Phase 2 LGD-4033, usually sold as ligandrol, is a nonsteroidal selective androgen receptor modulator that Viking Therapeutics took into clinical development under the code VK5211 (NCT02578095). t½ Long elimination half-life in humans with dose-proportional accumulation over 21 days of daily dosing in healthy young men; the report describes the profile without giving a single value in its summary (PMID: 22459616) Preclinical View Profile ](/compound/lgd-4033)[ ### Ostarine (Enobosarm, MK-2866) Performance Phase 3 Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22. t½ Not established from a retrieved human report; in rats the mean elimination half-life of radiolabeled GTx-024 was 0.6 h in males and 16.4 h in females (PMID: 24074268). Human plasma pharmacokinetics were characterized in phase 1 drug-interaction studies (PMID: 27105861) Preclinical View Profile ](/compound/ostarine)[ ### PEG-MGF Performance Preclinical PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of Mechano Growth Factor (MGF) — an alternatively spliced variant of IGF-1 produced locally in muscle and other tissues in response to mechanical loading or damage. t½ Native MGF: very short (minutes) due to rapid proteolysis. PEG-MGF: PEGylation is intended to extend this substantially (community estimates up to roughly 1 day), but there are no published human pharmacokinetic data to confirm a specific value. 200 Preclinical View Profile ](/compound/peg-mgf)[ ### SLU-PP-332 Performance Preclinical SLU-PP-332 is the first-generation synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by the laboratory of Thomas Burris at Saint Louis University and reported in a landmark 2023 publication that established ERR pan-agonism as a pharmacologically tractable exercise-mimetic drug mechanism. Research compound — no established human doses. Animal studies: 10-50 mg/kg 8 studies View Profile ](/compound/slu-pp-332)[ ### YK-11 Performance Preclinical YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. t½ Not established. In a human elimination study using deuterium-labeled YK-11, no intact parent compound was seen in urine; unconjugated metabolites disappeared within 24 hours and glucuronidated and sulfated metabolites remained traceable beyond 48 hours (PMID: 30379415) Preclinical View Profile ](/compound/yk-11) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-rad-140) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋